Mylan Crohn's Drug Doesn't Infringe AstraZeneca IP: Judge

Law360, Los Angeles (June 24, 2011, 3:06 PM EDT) -- A Delaware federal judge on Thursday ruled that Mylan Inc.'s generic version of Crohn's disease medication Entocort EC did not infringe a patent held by AstraZeneca Pharmaceuticals LP.

The ruling is a blow to AstraZeneca, which sued the generics maker's subsidiary, Mylan Pharmaceuticals Inc., in 2008, seeking to block its abbreviated new drug application for budesonide capsules — the generic version of Entocort. Mylan received final approval for the generic from the U.S. Food and Drug Administration on May 16.

Following Thursday's ruling, Mylan announced it...
To view the full article, register now.